Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

Gartanin is a novel NEDDylation inhibitor for induction of Skp2 degradation, FBXW2 expression, and autophagy.

Pham V, Rendon R, Le VX, Tippin M, Fu DJ, Le TH, Miller M, Agredano E, Cedano J, Zi X.

Mol Carcinog. 2019 Nov 29. doi: 10.1002/mc.23140. [Epub ahead of print]

PMID:
31782573
2.

Moorfields AMD database report 2: fellow eye involvement with neovascular age-related macular degeneration.

Fasler K, Fu DJ, Moraes G, Wagner S, Gokhale E, Kortuem K, Chopra R, Faes L, Preston G, Pontikos N, Patel PJ, Tufail A, Lee AY, Balaskas K, Keane PA.

Br J Ophthalmol. 2019 Oct 14. pii: bjophthalmol-2019-314446. doi: 10.1136/bjophthalmol-2019-314446. [Epub ahead of print]

PMID:
31611234
3.

Discovery of indoline derivatives that inhibit esophageal squamous cell carcinoma growth by Noxa mediated apoptosis.

Fu DJ, Li M, Zhang SY, Li JF, Sha B, Wang L, Zhang YB, Chen P, Hu T.

Bioorg Chem. 2019 Nov;92:103190. doi: 10.1016/j.bioorg.2019.103190. Epub 2019 Aug 10.

PMID:
31465969
4.

Corrigendum to "Synthesis and preliminary antiproliferative activity of new pteridin-7(8H)-one derivatives" [Eur. J. Med. Chem. 143 (2018) 1396-1405].

Li ZH, Zhao TQ, Liu XQ, Zhao B, Wang C, Geng PF, Cao YQ, Fu DJ, Jiang LP, Yu B, Liu HM.

Eur J Med Chem. 2019 Nov 1;181:111387. doi: 10.1016/j.ejmech.2019.05.077. Epub 2019 Jul 31. No abstract available.

PMID:
31376565
5.

Implementation of a cloud-based referral platform in ophthalmology: making telemedicine services a reality in eye care.

Kern C, Fu DJ, Kortuem K, Huemer J, Barker D, Davis A, Balaskas K, Keane PA, McKinnon T, Sim DA.

Br J Ophthalmol. 2019 Jul 18. pii: bjophthalmol-2019-314161. doi: 10.1136/bjophthalmol-2019-314161. [Epub ahead of print]

6.

Physical confinement induces malignant transformation in mammary epithelial cells.

Lu YC, Chu T, Hall MS, Fu DJ, Shi Q, Chiu A, An D, Wang LH, Pardo Y, Southard T, Danko CG, Liphardt J, Nikitin AY, Wu M, Fischbach C, Coonrod S, Ma M.

Biomaterials. 2019 Oct;217:119307. doi: 10.1016/j.biomaterials.2019.119307. Epub 2019 Jun 26.

PMID:
31271857
7.

One- and two-year visual outcomes from the Moorfields age-related macular degeneration database: a retrospective cohort study and an open science resource.

Fasler K, Moraes G, Wagner S, Kortuem KU, Chopra R, Faes L, Preston G, Pontikos N, Fu DJ, Patel P, Tufail A, Lee AY, Balaskas K, Keane PA.

BMJ Open. 2019 Jun 21;9(6):e027441. doi: 10.1136/bmjopen-2018-027441.

8.

Effect of total anti-VEGF treatment exposure on patterns of choroidal neovascularisation assessed by optical coherence tomography angiography in age-related macular degeneration: a retrospective case series.

Faes L, Ali Z, Wagner S, Patel PJ, Fu DJ, Bachmann LM, Schmid MK, Waheed N, Keane PA, Balaskas K.

BMJ Open Ophthalmol. 2019 Apr 9;4(1):e000244. doi: 10.1136/bmjophth-2018-000244. eCollection 2019.

9.

Discovery of novel chalcone-dithiocarbamates as ROS-mediated apoptosis inducers by inhibiting catalase.

Fu DJ, Li JH, Yang JJ, Li P, Zhang YB, Liu S, Li ZR, Zhang SY.

Bioorg Chem. 2019 May;86:375-385. doi: 10.1016/j.bioorg.2019.01.023. Epub 2019 Jan 16.

PMID:
30763884
10.

Molecular diversity of trimethoxyphenyl-1,2,3-triazole hybrids as novel colchicine site tubulin polymerization inhibitors.

Fu DJ, Li P, Wu BW, Cui XX, Zhao CB, Zhang SY.

Eur J Med Chem. 2019 Mar 1;165:309-322. doi: 10.1016/j.ejmech.2019.01.033. Epub 2019 Jan 18.

PMID:
30690300
11.

A detailed in vivo analysis of the retinal nerve fibre layer in choroideremia.

Fu DJ, Xue K, Jolly JK, MacLaren RE.

Acta Ophthalmol. 2019 Jun;97(4):e589-e600. doi: 10.1111/aos.13973. Epub 2018 Dec 21.

PMID:
30575280
12.

Identification of osimertinib (AZD9291) as a lysine specific demethylase 1 inhibitor.

Li ZR, Suo FZ, Hu B, Guo YJ, Fu DJ, Yu B, Zheng YC, Liu HM.

Bioorg Chem. 2019 Mar;84:164-169. doi: 10.1016/j.bioorg.2018.11.018. Epub 2018 Nov 16.

PMID:
30502627
13.

Mechanisms of synergistic neurotoxicity induced by two high risk pesticide residues - Chlorpyrifos and Carbofuran via oxidative stress.

Fu DJ, Li P, Song J, Zhang SY, Xie HZ.

Toxicol In Vitro. 2019 Feb;54:338-344. doi: 10.1016/j.tiv.2018.10.016. Epub 2018 Oct 30.

PMID:
30385350
14.

Bioactive heterocycles containing a 3,4,5-trimethoxyphenyl fragment exerting potent antiproliferative activity through microtubule destabilization.

Fu DJ, Yang JJ, Li P, Hou YH, Huang SN, Tippin MA, Pham V, Song L, Zi X, Xue WL, Zhang LR, Zhang SY.

Eur J Med Chem. 2018 Sep 5;157:50-61. doi: 10.1016/j.ejmech.2018.07.060. Epub 2018 Jul 29.

PMID:
30075402
15.

Optical limiting, nonlinear refraction and nonlinear absorption of the associates of Cd0.5Zn0.5S quantum dots and dyes.

Boltaev GS, Fu DJ, Sobirov BR, Smirnov MS, Ovchinnikov OV, Zvyagin AI, Ganeev RA.

Opt Express. 2018 May 28;26(11):13865-13875. doi: 10.1364/OE.26.013865.

PMID:
29877432
16.

Matrix metalloproteinase inhibitors enhance the efficacy of frontline drugs against Mycobacterium tuberculosis.

Xu Y, Wang L, Zimmerman MD, Chen KY, Huang L, Fu DJ, Kaya F, Rakhilin N, Nazarova EV, Bu P, Dartois V, Russell DG, Shen X.

PLoS Pathog. 2018 Apr 26;14(4):e1006974. doi: 10.1371/journal.ppat.1006974. eCollection 2018 Apr.

17.

Scalable Production and Cryostorage of Organoids Using Core-Shell Decoupled Hydrogel Capsules.

Lu YC, Fu DJ, An D, Chiu A, Schwartz R, Nikitin AY, Ma M.

Adv Biosyst. 2017 Dec;1(12). pii: 1700165. doi: 10.1002/adbi.201700165. Epub 2017 Nov 22.

18.

Bifactor Modeling of the Positive and Negative Syndrome Scale: Generalized Psychosis Spans Schizoaffective, Bipolar, and Schizophrenia Diagnoses.

Anderson AE, Marder S, Reise SP, Savitz A, Salvadore G, Fu DJ, Li Q, Turkoz I, Han C, Bilder RM.

Schizophr Bull. 2018 Oct 17;44(6):1204-1216. doi: 10.1093/schbul/sbx163.

19.

A Review of the Landscape of Targeted Immunomodulatory Therapies for Non-Infectious Uveitis.

Sharma SM, Fu DJ, Xue K.

Ophthalmol Ther. 2018 Jun;7(1):1-17. doi: 10.1007/s40123-017-0115-5. Epub 2017 Nov 30. Review.

20.

Design, synthesis and preliminary biological evaluation of 5,8-dihydropteridine-6,7-diones that induce apoptosis and suppress cell migration.

Geng PF, Wang CC, Li ZH, Hu XN, Zhao TQ, Fu DJ, Zhao B, Yu B, Liu HM.

Eur J Med Chem. 2018 Jan 1;143:1959-1967. doi: 10.1016/j.ejmech.2017.11.009. Epub 2017 Nov 5.

PMID:
29133051
21.

Synthesis and preliminary antiproliferative activity of new pteridin-7(8H)-one derivatives.

Li ZH, Zhao TQ, Liu XQ, Zhao B, Wang C, Geng PF, Cao YQ, Fu DJ, Jiang LP, Yu B, Liu HM.

Eur J Med Chem. 2018 Jan 1;143:1396-1405. doi: 10.1016/j.ejmech.2017.10.037. Epub 2017 Oct 16. Erratum in: Eur J Med Chem. 2019 Nov 1;181:111387.

PMID:
29113745
22.

Stem Cell Pathology.

Fu DJ, Miller AD, Southard TL, Flesken-Nikitin A, Ellenson LH, Nikitin AY.

Annu Rev Pathol. 2018 Jan 24;13:71-92. doi: 10.1146/annurev-pathol-020117-043935. Epub 2017 Oct 20. Review.

23.

A novel gene mutation of Runx2 in cleidocranial dysplasia.

Peng YJ, Chen QY, Fu DJ, Liu ZM, Mao TT, Li J, She WT.

J Huazhong Univ Sci Technolog Med Sci. 2017 Oct;37(5):772-776. doi: 10.1007/s11596-017-1803-z. Epub 2017 Oct 20.

PMID:
29058294
24.

Structure-Activity Relationship Studies of β-Lactam-azide Analogues as Orally Active Antitumor Agents Targeting the Tubulin Colchicine Site.

Fu DJ, Fu L, Liu YC, Wang JW, Wang YQ, Han BK, Li XR, Zhang C, Li F, Song J, Zhao B, Mao RW, Zhao RH, Zhang SY, Zhang L, Zhang YB, Liu HM.

Sci Rep. 2017 Oct 6;7(1):12788. doi: 10.1038/s41598-017-12912-4.

25.

Design and Antiproliferative Evaluation of Novel Sulfanilamide Derivatives as Potential Tubulin Polymerization Inhibitors.

Fu DJ, Liu JF, Zhao RH, Li JH, Zhang SY, Zhang YB.

Molecules. 2017 Sep 5;22(9). pii: E1470. doi: 10.3390/molecules22091470.

26.

Molecular diversity of phenothiazines: design and synthesis of phenothiazine-dithiocarbamate hybrids as potential cell cycle blockers.

Fu DJ, Zhao RH, Li JH, Yang JJ, Mao RW, Wu BW, Li P, Zi XL, Zhang QQ, Cai HJ, Zhang SY, Zhang YB, Liu HM.

Mol Divers. 2017 Nov;21(4):933-942. doi: 10.1007/s11030-017-9773-4. Epub 2017 Aug 7.

27.

Discovery of 5,6-diaryl-1,2,4-triazines hybrids as potential apoptosis inducers.

Fu DJ, Song J, Hou YH, Zhao RH, Li JH, Mao RW, Yang JJ, Li P, Zi XL, Li ZH, Zhang QQ, Wang FY, Zhang SY, Zhang YB, Liu HM.

Eur J Med Chem. 2017 Sep 29;138:1076-1088. doi: 10.1016/j.ejmech.2017.07.011. Epub 2017 Jul 8.

28.

Identification of thiazolo[5,4-d]pyrimidine derivatives as potent antiproliferative agents through the drug repurposing strategy.

Li ZH, Zhang J, Liu XQ, Geng PF, Ma JL, Wang B, Zhao TQ, Zhao B, Wei HM, Wang C, Fu DJ, Yu B, Liu HM.

Eur J Med Chem. 2017 Jul 28;135:204-212. doi: 10.1016/j.ejmech.2017.04.056. Epub 2017 Apr 22.

PMID:
28456031
29.

Paliperidone palmitate once-monthly maintains improvement in functioning domains of the Personal and Social Performance scale compared with placebo in subjects with schizoaffective disorder.

Fu DJ, Turkoz I, Walling D, Lindenmayer JP, Schooler NR, Alphs L.

Schizophr Res. 2018 Feb;192:185-193. doi: 10.1016/j.schres.2017.04.004. Epub 2017 Apr 26.

30.

Design and synthesis of formononetin-dithiocarbamate hybrids that inhibit growth and migration of PC-3 cells via MAPK/Wnt signaling pathways.

Fu DJ, Zhang L, Song J, Mao RW, Zhao RH, Liu YC, Hou YH, Li JH, Yang JJ, Jin CY, Li P, Zi XL, Liu HM, Zhang SY, Zhang YB.

Eur J Med Chem. 2017 Feb 15;127:87-99. doi: 10.1016/j.ejmech.2016.12.027. Epub 2016 Dec 14.

31.

Paliperidone Palmitate Once-Monthly Treatment in Recent Onset and Chronic Illness Patients With Schizoaffective Disorder.

Bossie CA, Turkoz I, Alphs L, Mahalchick L, Fu DJ.

J Nerv Ment Dis. 2017 Apr;205(4):324-328. doi: 10.1097/NMD.0000000000000646.

32.

Genome-wide association study of paliperidone efficacy.

Li Q, Wineinger NE, Fu DJ, Libiger O, Alphs L, Savitz A, Gopal S, Cohen N, Schork NJ.

Pharmacogenet Genomics. 2017 Jan;27(1):7-18.

33.

Impact of Paliperidone Palmitate Versus Oral Atypical Antipsychotics on Health Care Resource Use and Costs in Veterans with Schizophrenia.

Young-Xu Y, Duh MS, Muser E, DerSarkissian M, Faust E, Kageleiry A, Bhak RH, Fu DJ, Lefebvre P, Shiner B.

J Clin Psychiatry. 2016 Oct;77(10):e1332-e1341. doi: 10.4088/JCP.16m10745.

34.

Treatment Patterns and Antipsychotic Medication Adherence Among Commercially Insured Patients With Schizoaffective Disorder in the United States.

Joshi K, Lin J, Lingohr-Smith M, Fu DJ, Muser E.

J Clin Psychopharmacol. 2016 Oct;36(5):429-35. doi: 10.1097/JCP.0000000000000549.

35.

Benefit-risk assessment of paliperidone oral extended-release tablet versus monthly injectable for maintenance treatment of schizophrenia.

Levitan B, Markowitz M, Turkoz I, Fu DJ, Gopal S, Alphs L.

Int Clin Psychopharmacol. 2016 Nov;31(6):315-22. doi: 10.1097/YIC.0000000000000141.

36.

Design, synthesis and antiproliferative activity studies of novel dithiocarbamate-chalcone derivates.

Fu DJ, Zhang SY, Liu YC, Zhang L, Liu JJ, Song J, Zhao RH, Li F, Sun HH, Liu HM, Zhang YB.

Bioorg Med Chem Lett. 2016 Aug 15;26(16):3918-22. doi: 10.1016/j.bmcl.2016.07.012. Epub 2016 Jul 5.

PMID:
27423479
37.

Upregulated microRNA-301a in osteosarcoma promotes tumor progression by targeting CDC14A.

Ni Z, Shang XF, Wang YF, Sun YJ, Fu DJ.

Genet Mol Res. 2016 May 23;15(2). doi: 10.4238/gmr.15027807.

38.

Paliperidone Palmitate Once-Monthly Injectable Treatment for Acute Exacerbations of Schizoaffective Disorder.

Fu DJ, Turkoz I, Simonson RB, Walling D, Schooler N, Lindenmayer JP, Canuso C, Alphs L.

J Clin Psychopharmacol. 2016 Aug;36(4):372-6. doi: 10.1097/JCP.0000000000000535.

39.
40.

Design, Synthesis and Structure-Activity Relationships of Novel Chalcone-1,2,3-triazole-azole Derivates as Antiproliferative Agents.

Zhang SY, Fu DJ, Yue XX, Liu YC, Song J, Sun HH, Liu HM, Zhang YB.

Molecules. 2016 May 19;21(5). pii: E653. doi: 10.3390/molecules21050653.

41.

Factors associated with relapse in schizophrenia despite adherence to long-acting injectable antipsychotic therapy.

Alphs L, Nasrallah HA, Bossie CA, Fu DJ, Gopal S, Hough D, Turkoz I.

Int Clin Psychopharmacol. 2016 Jul;31(4):202-9. doi: 10.1097/YIC.0000000000000125.

PMID:
26974214
42.

Paliperidone for the treatment of schizoaffective disorder.

Alphs L, Fu DJ, Turkoz I.

Expert Opin Pharmacother. 2016;17(6):871-83. doi: 10.1517/14656566.2016.1161029. Epub 2016 Mar 24. Review.

PMID:
26934062
43.

An Arthroscopic Second-Look Study on the Effect of Remnant Preservation on Synovialization of Bone-Patellar Tendon-Bone Allograft in Anterior Cruciate Ligament Reconstruction.

Guo L, Chen H, Luo JM, Yang L, Gu LC, Fu DJ.

Arthroscopy. 2016 May;32(5):868-77. doi: 10.1016/j.arthro.2015.11.017. Epub 2016 Jan 25.

PMID:
26821962
44.

Rapid onset of treatment effects on psychosis, depression, and mania in patients with acute exacerbation of schizoaffective disorder following treatment with oral extended-release paliperidone.

Fu DJ, Turkoz I, Bossie CA, Patel H, Alphs L.

J Affect Disord. 2016 Mar 15;193:381-90. doi: 10.1016/j.jad.2015.12.060. Epub 2015 Dec 31.

45.

Comparison of Medicaid spending in schizoaffective patients treated with once monthly paliperidone palmitate or oral atypical antipsychotics.

Xiao Y, Muser E, Fu DJ, Lafeuille MH, Pilon D, Emond B, Wu A, Duh MS, Lefebvre P.

Curr Med Res Opin. 2016;32(4):759-69. doi: 10.1185/03007995.2016.1140634. Epub 2016 Feb 2.

PMID:
26750639
46.

Efficient three-component one-pot synthesis of steroidal polysubstituted anilines.

Zhang YL, Li YF, Shi YK, Yu B, Zhang GC, Qi PP, Fu DJ, Shan LH, Liu HM.

Steroids. 2015 Dec;104:1-7. doi: 10.1016/j.steroids.2015.07.005. Epub 2015 Jul 22.

PMID:
26209811
47.

Comparing Injection Site Pain with Paliperidone Palmitate Versus First-Generation Depot Antipsychotics in Subjects with Schizophrenia.

Gopal S, Palermo T, Sliwa JK, Nuamah I, Fu DJ, Alphs L.

Innov Clin Neurosci. 2015 May-Jun;12(5-6):10-1. No abstract available.

48.

Estimated medical cost reductions for paliperidone palmitate vs placebo in a randomized, double-blind relapse-prevention trial of patients with schizoaffective disorder.

Joshi K, Lin J, Lingohr-Smith M, Fu DJ.

J Med Econ. 2015;18(8):629-36. doi: 10.3111/13696998.2015.1033424. Epub 2015 Apr 22.

PMID:
25800457
49.

Large-scale candidate gene study to identify genetic risk factors predictive of paliperidone treatment response in patients with schizophrenia.

Wang D, Fu DJ, Wu X, Shapiro A, Favis R, Savitz A, Chung H, Alphs L, Gopal S, Haas M, Cohen N, Li Q.

Pharmacogenet Genomics. 2015 Apr;25(4):173-85. doi: 10.1097/FPC.0000000000000122.

PMID:
25714000
50.

Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder.

Fu DJ, Turkoz I, Simonson RB, Walling DP, Schooler NR, Lindenmayer JP, Canuso CM, Alphs L.

J Clin Psychiatry. 2015 Mar;76(3):253-62. doi: 10.4088/JCP.14m09416.

Supplemental Content

Support Center